Gonorrhea - Drug Pipeline Landscape, 2023

Gonorrhea - Drug Pipeline Landscape, 2023

Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Gonorrhea most often affects the urethra, rectum or throat. In females, gonorrhea can also infect the cervix.

Symptoms of Gonorrhea infection in men include painful urination, pain or swelling in one testicle and in women include increased vaginal discharge, painful urination, vaginal bleeding between periods and abdominal or pelvic pain.

Diagnosis of Gonorrhea can be done after analyzing a sample of cells. Samples can be collected by urine test or swab of affected area.

Treatment for Gonorrhea include one-time intramuscular injection of the antibiotic ceftriaxone.

Some companies that are active in the development of gonorrhea drugs include Evofem Inc., GlaxoSmithKline, and Entasis Therapeutics.

There are several clinical trials currently ongoing in gonorrhea drug development. The most promising trials are testing new antibiotics against gonorrhea bacteria. These new antibiotics are designed to be more effective against gonorrhea bacteria than existing antibiotics. Other ongoing trials are testing vaccine candidates against gonorrhea. These vaccines are designed to prevent gonorrhea infections by inducing an immune response against the bacteria.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Gonorrhea treatment such as EVO100, Gepotidacin, Zoliflodacin and others. Key players involved in the development of therapies to treat Gonorrhea are Alopexx Pharmaceuticals Inc, Biolytics Pharma, Entasis Therapeutics, Evofem Inc, GlaxoSmithKline and others. Three drugs are under late-stage Phase III clinical trials and some other drugs are under preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Gonorrhea - Drug Pipeline Landscape, 2023 report provides an overview of the Gonorrhea pipeline drugs. This report covers detailed insights on Gonorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gonorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.